NCT03184363Unknown3 期
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines: Multi-center, Single Arm, Open, Extension Study
Daewoong Pharmaceutical Co. LTD.0 个研究点目标入组 102 人开始时间: 2017年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 102
- 主要终点
- Subject Assessment of Satisfaction of Appearance
研究概览
简要总结
The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of at least 18 to 75 years old
- •moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
- •moderate-to-severe GL at maximum frawn on the FWS as rated by the investigator
- •Subject who has completed phase 3 study for CFL.
排除标准
- 未提供
研究组 & 干预措施
Clostridium Botulinum A Toxin
Experimental
Clostridium Botulinum A Toxin
干预措施: Clostridium Botulinum A Toxin (Drug)
结局指标
主要结局
Subject Assessment of Satisfaction of Appearance
时间窗: At 4 weeks
Subject Assessment of Satisfaction of Appearance
次要结局
未报告次要终点
研究者
相似试验
Unknown
2 期
Efficacy and Safety of DWP450 for the Treatment of Crows Feet LinesCrows Feet LinesNCT02882893Daewoong Pharmaceutical Co. LTD.238
已完成
2 期
Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic NeuralgiaPostherpetic NeuralgiaNCT01557010Daewoong Pharmaceutical Co. LTD.140
已完成
3 期
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001Glabellar Frown LinesNCT02334423Evolus, Inc.330
已完成
3 期
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002Glabellar Frown LinesNCT02334436Evolus, Inc.324
已完成
3 期
Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)Functional DyspepsiaNCT03184402Daewoong Pharmaceutical Co. LTD.124